Laboratory and clinical studies on pazufloxacin in the surgical field

Abstract

We performed laboratory and clinical studies on pazufloxacin (PZFX). The antibacterial activities of PZFX against clinical isolates were tested and compared with those of cefaclor (CCL), ofloxacin (OFLX) and tosufloxacin (TFLX).
The MICs of PZFX against coagulase-positive staphylococci ranged from 0.1 to 50μg/ml. The MICs of PZFX against coagulase-negative staphylococci ranged from 0.8 to 25μg/ml. These activities against coagulase-positive and-negative staphylococci were twofold inferior to those of TFLX and comparable or twofold superior to those of OFLX. Most strains of MRSA were not susceptible to PZFX. The antibacterial activities of PZFX against Escherichia coli were very good with the MIC range of ≤0.05 to 6.25μg/ml. The MICs of PZFX against Klebsiella pneumoniae were also very low values and ranged from ≤0.05 to 0.2μg/ml. The MICs of PZFX against Enterobacter cloacae ranged from ≤0.05 to 100μg/ml. The MICs of PZFX against resistant strains (nine of twenty seven strains) ranged from 6.25 to 100μg/ml, but against other strains the MICs of PZFX ranged from ≤0.05 to 0.2μg/ml.
The MICs of PZFX against Pseudomonas aeruginosa ranged from ≤0.05 to 50μg/ml, but against most strains (twenty two of twenty seven) they ranged from 0.4 to 1.56μg/mi. These activities against P.aeruginosa were comparable to those of TFLX and twofold superior to those of OFLX.
The serum concentrations of PZFX in these clinical cases were measured. In the cases of 100mg administration, serum concentrations ranged from 0.239 to 1.48μg/ml. In those of 200 mg administration, serum concentrations ranged from 0.72 to 4.17μg/ml.
In one case, nausea appeared when PZFX was administered, but no additional treatment was needed and administration was continued. No other side effects were noted.